Saira Ramasastry - 08 Sep 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
Director
Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Issuer symbol
MIRM
Transactions as of
08 Sep 2025
Net transactions value
+$399,670
Form type
4
Filing time
10 Sep 2025, 17:50:37 UTC
Previous filing
04 Jun 2025
Next filing
07 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ramasastry Saira Director C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY /s/ Judit Ryvkin, Attorney-in-Fact 10 Sep 2025 0001547959

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Options Exercise $399,670 +17,000 $23.51 17,000 08 Sep 2025 Direct
transaction MIRM Common Stock Sale -17,000 -100% 0 08 Sep 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Stock Option (right to buy) Options Exercise $0 -17,000 -50% $0.000000 17,000 08 Sep 2025 Common Stock 17,000 $23.51 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average sale price for the transaction reported was $77.042178, and the range of prices were between $76.835 and $77.29. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F2 The stock option is fully vested.